Douglas Lu, DC
Family · San Antonio, TXNPI 1013925130
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 259 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,363 and has fallen 79.2% since, to $284 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$642
- Neurocrine Biosciences, Inc.$481
- Amgen$450
- Teva Pharmaceuticals USA, Inc.$406
- Johnson & Johnson$228
- EMD Serono, Inc.$180
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,348100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 26 | $642 |
| Neurocrine Biosciences, Inc. | 38 | $481 |
| Amgen | 31 | $450 |
| Teva Pharmaceuticals USA, Inc. | 21 | $406 |
| Johnson & Johnson(2 entities) | 12 | $228 |
| EMD Serono, Inc. | 10 | $180 |
| Livanova USA, Inc. | 9 | $176 |
| SK Life Science, Inc. | 10 | $173 |
| Eisai Inc. | 9 | $162 |
| GE HealthCare | 7 | $133 |
| Pfizer | 7 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Biogen | 4 | $84 |
| AstraZeneca | 4 | $80 |
| Sunovion Pharmaceuticals Inc. | 16 | $79 |
| Impel Pharmaceuticals Inc. | 5 | $79 |
| Kyowa Kirin, Inc. | 4 | $70 |
| AbbVie | 3 | $67 |
| Lilly USA, LLC | 4 | $64 |
| Avion Pharmaceuticals | 3 | $59 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| MDD US Operations, LLC | 4 | $51 |
| Bioventus LLC | 2 | $46 |
| Corium, LLC | 3 | $44 |
| Octapharma USA, Inc. | 2 | $40 |
| Acorda Therapeutics, Inc | 2 | $37 |
| Lundbeck LLC | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Vertex | 1 | $30 |
| Sandoz | 2 | $28 |
| GRT US Holding, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sumitomo Pharma America, Inc. | 3 | $14 |
How this compares
$4,348 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 19 | $526 |
| Ibuprofen | 11 | $101 |
| Meloxicam | 15 | $14 |
Paid to pharmacies, not to this prescriber.
Other family in San Antonio
- Anna CastroSan Antonio$184K
- Natalia FariasSan Antonio$124K
- Tina CoppleSan Antonio$97K
- Kim HinojosaSan Antonio$63K
- Kimberly GibergaSan Antonio$36K
- Febbie PhiriSan Antonio$31K
- Annette GantzSan Antonio$31K
- Renee ChisumSan Antonio$28K
- Thimios PartalasSan Antonio$27K
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.